Following results from a phase 2 study of FOL-005, for the treatment of hair loss, the Board of the company decided to evaluate the company’s business strategy and long-term goals.
Pharma news from the Nordic life science industry
Calliditas Therapeutics has announced that the U.S. Food and Drug Administration has extended the PDUFA goal date for its New Drug Application (NDA) seeking accelerated approval for Nefecon to December
Diamyd Medical has announced the acquisition of the property in Umeå where production of the recombinant protein GAD65, the active component in the therapeutic diabetes vaccine Diamyd is being established.
Immunovia has strengthened its patent protection for pancreatic cancer biomarkers by obtaining a global license from the South Korean company JW BioScience’s IP portfolio. The license agreement gives Immunovia global
Sprint Bioscience is broadening its pipeline with an additional drug program for the treatment of solid tumors. The program goes by the program name NIMA and aims to develop drugs
Diamyd Medical has successfully completed a directed share issue of 5 357 143 B-shares at a price of SEK 28 per share. Through the Directed Share Issue, the company will
The company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combination study with the company’s leading candidate drug MIV-818
Ultomiris (ravulizumab) has been approved in the European Union for expanded use to include children and adolescents with paroxysmal nocturnal haemoglobinuria (PNH), an ultra-rare and severe blood disorder characterized by
Investor AB has undertaken to accept the public offer made September 2, by Agnafit Bidco for the shares in Swedish Orphan Biovitrum at a price per share of SEK 235.
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).
Saniona announced July 26th that the U.S. Food and Drug Administration had granted orphan drug designation to Tesomet for the treatment of hypothalamic obesity (HO). Tesomet is the first and
AlzeCure Pharma has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on
Cantargia receives regulatory approval to start CESTAFOUR clinical study with nadunolimab in combination with chemotherapy. The company has announced approval to start the phase I/II clinical study by the regulatory
Positive results from the Phase III trial showed that AstraZeneca’s Imfinzi and tremelimumab, when added to platinum-based chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS)
The two companies have announced dosing of the first patient in the global ASPIRE Phase 2 trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of Ankylosing Spondylitis (AS). ASPIRE
Positive results from the trial in Wilson disease showed that ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilization from tissues, demonstrating superiority compared
The company expands the trial after successful completion of recruitment in the pembrolizumab combination arm. The last patient in the initial treatment arm of the phase Ib clinical study CIRIFOUR
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77%, compared to placebo. The Phase III trial accrued 25 cases of symptomatic COVID-19
Alexion, AstraZeneca Rare Disease, is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). Alexion, AstraZeneca Rare Disease, is the group
The company has announced that the publication of the trial including 12,750 men has been fast tracked and is now published in The Lancet Oncology. Results from the trial demonstrated
Pharmaceuticals in the environment is a growing problem of global concern. Drugs taken by humans and animals find their way into rivers, lakes and even drinking water and can have
CDMO Recipharm has announced that its 2020 International Environmental Award will be presented to Amy Pruden, Professor of Civil and Environmental Engineering at Virginia Tech in Blacksburg, Virginia, US. Amy
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain